The human central nervous system (CNS) is subject to various diseases – neurological disorders, the treatment of which often generates complex neuroscience conundrums. Advances in diagnosis, prevention and therapy of brain disabilities pose a serious challenge and require a lot of time and tremendous efforts. In particular, CNS-targeted drug design and development has been extremely problematic [1-3] owing to the diversity of CNS illnesses and the difficulty of drug delivery through the blood-brain barrier (BBB) . As a result, many known brain diseases still stand in need of cure or effective medical treatment.
To raise public awareness of neurological diseases and to highlight the topical issues related to brain health, the World Federation of Neurology marks the World Brain Day every year on July 22nd. Previous campaigns touched on the problems of epilepsy, dementia, stroke, migraine, as well as general matters of brain-affecting diseases.
The World Brain Day 2020 spotlights issues and challenges associated with Parkinson’s disease – a chronic degenerative CNS disorder that affects almost all brain functions [5-7]. It causes motor and mental disabilities, and symptoms get gradually but inevitably worse over time. The existing treatment strategies focus on maintaining patients’ quality of life rather than cure [8, 9], whereas the discovery of novel drugs capable of hindering the relentless neurodegenerative progression remains an unmet need.
With this year’s World Brain Day, the World Federation of Neurology and the International Parkinson and Movement Disorder Society aim to attract global attention to the continuing prevalence of Parkinson’s disease and to stress the demand for headway in disease-related studies.
To facilitate the research advances in CNS drug design Life Chemicals is offering a dedicated selection of CNS-related Libraries for exploration of chemical space of potential CNS drugs in test models of Parkinson’s disease, Alzheimer’s disease, and many other complex neurological disorders and conditions:
- CNS Screening Library
- N-methyl-D-aspartate (NMDA) Receptor Screening Library
- Ion Channel Screening Libraries
- Matrix Metalloproteinase Focused Library
- GPCR Screening Libraries
- ATPase Focused Libraries
- Nuclear Receptor Screening Libraries
- Phenotypic Screening Libraries
These expertly designed targeted and focused libraries cover a broad range of CNS drug targets and address critical needs for general CNS-oriented compounds (as demonstrated by our CNS Screening Library and Phenotypic Screening Libraries). The compounds in these Libraries are selected with a variety of computational approaches that include molecular docking, pharmacophore search and chemoinformatics data analysis, and, thus, may be of great value for CNS-related research.
Please, contact us at email@example.com for any details, specific requirements, and price quotations.
Love yoga and gym? Your brain also wants to stay fit! Take a pause and have some fun with our puzzle!
- Danon, J. J., Reekie, T. A., & Kassiou, M. (2019). Challenges and Opportunities in Central Nervous System Drug Discovery. Trends in Chemistry. doi:10.1016/j.trechm.2019.04.009
- Gribkoff, V. K., & Kaczmarek, L. K. (2017). The need for new approaches in CNS drug discovery: Why drugs have failed, and what can be done to improve outcomes. Neuropharmacology, 120, 11–19. doi:10.1016/j.neuropharm.2016.03.021
- Banks, W. A., & Greig, N. H. (2019). Small molecules as central nervous system therapeutics: old challenges, new directions, and a philosophic divide. Future Medicinal Chemistry. 11(6):489-493. doi:10.4155/fmc-2018-0436
- Pardridge, W. M. (2007). Blood–brain barrier delivery. Drug Discovery Today, 12(1-2), 54–61. doi:10.1016/j.drudis.2006.10.013
- Chaudhuri, K. R., & Fung, V. S. (2016). Fast facts: Parkinson's disease. Karger Medical and Scientific Publishers. DOI: 10.1159/isbn.978-1-910797-22-8
- Hirsch, L., Jette, N., Frolkis, A., Steeves, T., & Pringsheim, T. (2016). The Incidence of Parkinson’s Disease: A Systematic Review and Meta-Analysis. Neuroepidemiology, 46(4), 292–300. doi:10.1159/000445751
- Raza, C., Anjum, R., & Shakeel, N. ul A. (2019). Parkinson’s disease: Mechanisms, translational models and management strategies. Life Sciences, 226, 77–90. doi:10.1016/j.lfs.2019.03.057
- Oertel, W. H. (2017). Recent advances in treating Parkinson’s disease. F1000Research, 6, 260. doi:10.12688/f1000research.10100.1
- Hajj, R. (2018). Parkinson Disease Therapies and Drugs. Pathology, Prevention and Therapeutics of Neurodegenerative Disease, 151–158. doi:10.1007/978-981-13-0944-1_13